Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MaaT013 for Ruxolitinib-Refractory GI-aGVHD
NCT04769895Phase 3Active, not recruiting
- Sponsor
- MaaT Pharma
- Start
- Mar 2022
- Primary completion
- Nov 2024
- Modality
- Live Biotherapeutic Products, Device-based Delivery
- Countries
- 6
01
Overview
A Phase 3 trial of MaaT013 in Acute Graft-Versus-Host Disease (aGvHD), sponsored by MaaT Pharma. Started Mar 2022; status: active, not recruiting.
02
Drugs
MaaT013
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04769895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04769895.